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Raynaud’s syndrome (RS) is characterized by episodic digital ischemia induced by cold or emotional stress. Pathophys-
iologic mechanisms include temporary vasospasm and ﬁxed digital artery obstruction. A number of pharmacologic and
invasive therapies have been studied to treat RS symptoms; however, there are no speciﬁc treatments that are currently
approved by the U.S. Food and Drug Administration speciﬁcally for RS. Of the available pharmacologic agents, calcium-
channel blockers remain the preferred initial treatment for vasospastic RS, although many vasodilators have been studied
and found to be efﬁcacious. Vasodilators are less effective in treating digital artery obstruction, and no treatments have
been found to be universally beneﬁcial, although the phosphodiesterase V inhibitors have been gaining in popularity.
Invasive therapies may have a role in selective cases. In this review, the current evidence of treatment for RS is sum-
marized. (J Vasc Surg 2013;57:1710-6.)Initially described in 1862, Raynaud’s syndrome (RS)
remains a poorly understood clinical condition. Typically
characterized by cold- or stress-induced skin color changes
(blanching, followed by cyanosis, followed by hyperemia),
the underlying pathophysiologic mechanism has not yet
been elucidated; however, alterations in peripheral adreno-
ceptor activity has been implicated, speciﬁcally either an
overexpression or hyperactivity of postsynaptic alpha 2
receptors leading to enhanced smooth muscle contraction.
RS can occur as an isolated entity, historically referred to as
Raynaud disease or primary RS, or in association with other
conditions, most frequently the connective tissue diseases
(eg, scleroderma, systemic lupus erythematosus, rheuma-
toid arthritis, and Sjögen’s syndrome), often referred to
as Raynaud phenomenon or secondary RS.
The diagnosis of RS remains primarily clinical, based on
patient descriptions of cold or emotionally induced skin
changes. As witnessed events are rare in the clinic setting,
the authors often ask patients to bring photos of their
events. Upper extremity pulse volume recording is often
performed to rule out proximal arterial obstruction. Digital
pressures and photoplethysmographic waveforms are used
to differentiate between patients with underlying vaso-
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0decreased pressures and blunted waveforms. Laser Doppler
and digital thermography have been used primarily in
research studies but have not found widespread clinical
use. Cold challenge testing, such as ice water immersion
with temperature recovery, are highly sensitive but lack
speciﬁcity. The authors also perform serologic screening
(antinuclear antibody and rheumatoid factor) for associated
connective tissue disorders.
Most patients with RS can be managed conservatively,
with avoidance of cold exposure or hand warming. For
those in whom conservative management is inadequate,
a number of pharmacologic, surgical, and behavioral ther-
apies have been used. Due to lack of complete under-
standing of the underlying pathophysiology, targeted
therapy has not been possible; rather, therapy has focused
on the use of general vasodilatory strategies. Connective
tissue disorders associated with secondary RS are frequently
managed with immunosuppression or immunomodulation.
These agents independently have not been shown to treat
RS symptoms, so concurrent therapy with vasodilatory
agents is often appropriate.
Clinical trials examining therapies are difﬁcult to
compare due to lack of established endpoints, most trials
using frequency or duration of RS attacks, visual analog
scales for pain, or less frequently, measures of digital artery
perfusion. It is important to note that while many pharma-
cologic agents have been investigated, none are currently
approved by the U.S. Food and Drug Administration for
use in RS. In this review, current medical, surgical and
alternative therapy is summarized.METHODS
A Medline and Cochrane database review was per-
formed for Raynaud disease from 1964 to 2012. Relevant
randomized controlled trials and meta-analyses were
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controlled trials nor meta-analyses were available, noncon-
trolled trials and case series were evaluated. Data from
multiple trials were summarized in tabular form. Highest
level of evidence was categorized according to the U.S.
Preventive Services Task Force classiﬁcation.1
RESULTS
Medical therapy. Pharmacologic therapy is indicated
for patients whose symptoms do not respond to simple
conservative measures, such as avoidance of cold and
tobacco exposure and hand warming. Some patients
require medications only during cold winter months. The
goal of medical therapy is to decrease the frequency and
intensity vasospastic attacks rather than to cure the under-
lying cause. Currently used medications for both primary
and secondary RS are listed in Table I.
Calcium-channel blockers. Calcium-channel blockers
are the most extensively researched medications and remain
ﬁrst-line therapy for RS. Drugs in the dihydropyridine class
are more potent vasodilators than the non-dihydropyridine
classes, but also more frequently associated with side
effects. Long-acting or sustained-release preparations are
preferred. Diltiazem is less potent and consequently has
fewer adverse effects, but is also less efﬁcacious.2 Verapamil
has more cardiac than peripheral vascular selectivity and is
not a good peripheral vasodilator.
Nifedipine is considered by many to be the drug of ﬁrst
choice for RS. A 66% reduction in frequency of attacks has
been reported in a recent multicenter, randomized,
controlled trial of 313 patients with primary RS treated
with sustained-release nifedipine compared with placebo.3
Adverse side effects resulting in discontinuation of nifedi-
pine occurred in 15% of patients. A recent meta-analysis
of 12 randomized, controlled trials demonstrated an overall
reduction in severity of attacks graded on a visual analog
scale of 33%, with an average of 2.8 to 5.0 fewer attacks
per week in patients treated with nifedipine.4
Other dihydropyridines have also been used in RS.
Amlodipine5 is similar to nifedipine but has a longer half-
life, with the theoretical advantage of fewer adverse effects.
Nicardipine,6,7 in most studies, has been shown to be effec-
tive in the treatment of vasospasm and can be administered
by oral or intravenous route. Felodipine8 and nisoldipine9
have also been shown to be efﬁcacious in small, random-
ized European trials.
Alpha 1-adrenergic blockers. Sympathetic nerve stim-
ulation results in norepinephrine release, which acts on
the alpha 1 receptor located on vascular smooth muscle,
causing vasoconstriction. This action is competitively
inhibited by alpha 1-selective blockers. At the same time,
thepresynaptic alpha2 receptor located on thenerve terminal
remains intact, preventing the tachycardia seen with nonse-
lective alpha blockers.
Prazosin is a selective alpha 1-adrenergic antagonist
that signiﬁcantly reduces the number of attacks in both
primary and secondary RS.10 Side effects include postural
hypotension, usually resolving within several days astolerance develops. In a double-blind, placebo-controlled,
crossover study of 24 patients, prazosin was reported supe-
rior to placebo in the treatment of RS. Subjective beneﬁt
with signiﬁcant reduction in number and duration of
attacks was noted in two-thirds of those patients treated
with prazosin compared with placebo, with improvement
in ﬁnger blood ﬂow assessed during a ﬁnger cooling
test.11 Long-acting forms of prazosin include doxazosin12
and terazosin,13 which allow once-daily dosing. These
drugs have also been shown to be effective therapy for
treatment for RS by decreasing the number, intensity,
and duration of attacks.
Renin-angiotensin system mediators. Mediators of
the renin-angiotensin system, such as angiotensin-convert-
ing enzyme (ACE) inhibitors and angiotensin II receptor
blockers, are indirect vasodilators that can counteract the
effects of angiotensin II, a potent vasoconstrictor.
ACE inhibitors. Captopril has been used most exten-
sively of the ACE inhibitors for the treatment of RS. In
a randomized controlled crossover trial of 15 subjects
with primary RS, captopril caused a signiﬁcant increase in
cutaneous blood ﬂow measured both with laser Doppler
ﬂowmetry and photoplethysmography, but no change in
frequency or severity of RS attacks was noted.14 Enalap-
ril15 and quinapril16 have not been shown to be effective in
clinical trials.
Angiotensin II receptor blockers. Losartan is an
angiotensin II receptor type 1 antagonist. In a recent
randomized controlled study, losartan 50 mg daily was
found to be more effective than nifedipine 40 mg daily in
reducing the frequency and severity of vasospastic episodes
in patients with primary RS and those with secondary RS
due to systemic sclerosis following 12 weeks of therapy.17
No signiﬁcant differences were seen between the two
groups in laser Doppler ﬂow following cold challenge.
Signiﬁcantly fewer adverse effects were noted in the los-
artan group compared with those taking nifedipine (39% vs
12%; P ¼ .005). While promising, larger trials with longer
follow-up are required to more clearly deﬁne the role of
losartan in the treatment of RS.
Serotonin reuptake inhibitors. Serotonin acts as a
vasoconstrictor in vivo. Fluoxetine, a selective serotonin
reuptake inhibitor, was shown to reduce the frequency
and severity of attacks in both primary and secondary RS
in a randomized cross-over trial with nifedipine. Labora-
tory testing showed improvement in recovery after a cold
challenge test, with the greatest improvement seen in
women with primary RS.18
Phosphodiesterase inhibitors. The phosphodies-
terase type 5 (PDE5) inhibitors sildenaﬁl, tadalaﬁl, and var-
denaﬁl have recently been evaluated in the treatment of
secondary RS. These medications are selective inhibitors
of cGMP-speciﬁc PDE5, which increases cGMP, result-
ing in enhanced cGMP-dependent micro- and macro-
vascular dilatation. Thus, in addition to their use in the
treatment of erectile dysfunction, the PDE5 inhibitors have
been investigated for use in nonerectile indications such as
pulmonary hypertension and RS.
Table I. Medical therapy for Raynaud’s syndrome (RS)
Drug class Drug names Dosage
Highest level
of evidence Results Most frequent side effects
Calcium channel
blockers
(dihydropyridine)
Nifedipine 10-30 mg po qd-tid 1 33%-66% reduction in
frequency and severity of
attacks; most extensively
studied medication
Hypotension, ﬂushing,
edema, palpitations,
dizziness (similar for
entire class of drugs)
Nicardipine 20-50 mg po bid 1 Mixed results compared with
placebo
Amlodipine 10 mg po qd 1 27% reduction in frequency of
attacks
Felodipine 5-20 mg po qd 1 Similar to nifedipine in small
trial
Nisoldipine 5-10 mg po qd 1 Mixed results improving
severity and frequency of
attacks
Calcium channel
blockers (non-
dihydropyridine)
Diltiazem 30-120 mg po tid 1 Some improvement but less
efﬁcacious than
dihydropyridine class
Fewer side effects than
dihydropyridine class
Verapamil No proven beneﬁt
Alpha 1 receptor
antagonists
Prazosin 1 mg po tid 1 1-2 fewer attacks per day,
decreased duration; modest
beneﬁt in secondary RS
Terazosin
Doxazosin
1mg po qhs
1mg po qhs
3
3
Not systematically studied Orthostatic
hypotension;
palpitations
Renin-angiotensin
system mediators
(ACE inhibitors)
Captopril 12.5-25 mg po bid-tid 1 Improved ﬁnger blood ﬂow;
symptom relief mixed
Dry cough, headache,
fatigue, dizziness
(similar for entire
drug class)
Enalopril 20 mg po qd 1 Mixed results in clinical trials
Quinapril 80 mg po qd 1 No clinical beneﬁt
Renin-angiotensin
system mediators
(angiotensin II
receptor blockers)
Losartan 12.5-50 mg po qd 1 Up to 50% reduction in
severity and frequency of
attacks
Dizziness
Serotonin reuptake
inhibitors
Fluoxetine 20-40 mg po qd 1 Signiﬁcant decrease in severity
and frequency of attacks vs
nifedipine
Headaches, nausea,
palpitations, lethargy
Phosphodiesterase V
inhibitors
Sildenaﬁl 50 mg po qd-bid
Extended release 100-
200 mg qd
1 Decreased duration and
frequency of attacks;
improvement of capillary
blood ﬂow; beneﬁt primarily
in secondary RS
Headache, ﬂushing,
nausea, muscle pain,
dyspepsia, dizziness
(similar for all drugs in
this class)
Tadalaﬁl 20 mg every other day 1 Decreased frequency and
duration of attacks and
improved ulcer healing as
add on therapy; less
beneﬁcial as monotherapy
Vardenaﬁl 10 mg po bid 2 Improved digital blood ﬂow
and symptoms in secondary
RS
Nitrates Topical
nitroglycerin
(MQX-503)
0.5 gm of gel up to
four times a day
1 Improved Raynaud Condition
Score, no change in duration
or frequency of attacks
Headache, upper
respiratory tract
infection; dizziness
Prostaglandins Epoprostenol 1-2 ng/kg/min iv 1 Decreased severity of
symptoms in patients with
scleroderma and pulmonary
hypertension
Flushing, headache,
nausea, vomiting,
hypotension
Iloprost 0.5-2 ng/kg/min iv
or 50 microgm po
bid
IV form effective in ulcer
healing and reducing
symptoms. PO form not
more effective than placebo
Headache, nausea,
vomiting
Endothelin receptor
antagonist
Bosentan 62.5 mg po bid 1 Decreased new ulcer formation
in patients with scleroderma.
No effect on healing of
existing ulcers
Elevated hepatic
transaminases,
peripheral edema
ACE, Angiotensin-converting enzyme; bid, twice a day; iv, intravenous; po, orally; qd, once a day; qhs, every evening; tid, three times a day.
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Table II. Surgical and other invasive therapy for
Raynaud’s syndrome (RS)
Invasive therapy
Highest level
of evidence Results
Botulinum toxin 3 Improved pain and ulcer
healing in small case series
Sympathetic block 3 Improved ulcer healing in
small case series
Thoracoscopic
sympathectomy
3 High recurrence rate in
primary RS; improved
ulcer healing and pain
control in selected patients
with secondary RS
Digital
sympathectomy
3 Anecdotal reports of
improved pain and ulcer
healing
Spinal cord
stimulators
3 Reduced pain and improved
ulcer healing in small case
series
Table III. Behavioral and alternative therapy for
Raynaud’s syndrome (RS)
Therapy
Level of
evidence Results
Biofeedback 1 Results inferior to nifedipine in large
RCT
Acupuncture 1 Single small RCT showed decreased
number and duration of attacks in
patients with primary RS
Laser therapy 1 Single small RCT showed decreased
frequency and intensity of attacks
Gingko biloba 1 Decrease in event rates but not
frequency or severity; small trial
with limited statistical power
RCT, Randomized controlled trial.
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A placebo-controlled, double-blind crossover trial com-
paring 4 weeks of therapy with sildenaﬁl, 50 mg twice daily,
vs placebo was performed in 16 subjects with secondary
RS not responsive to vasodilator therapy.19 Signiﬁcant
improvements in Raynaud’s Condition Score, a 0-10 scale
that incorporates frequency and severity of attacks, and
capillary blood ﬂow, as measured by laser Doppler, were
detected with sildenaﬁl therapy, regardless of the order of
treatment. The frequency of RS attacks was reduced by
33%, and the duration of attacks reduced by 44% with sil-
denaﬁl therapy in comparison with placebo. Beneﬁcial
effects on ulcer healing were also observed, and only two
patients had side effects requiring cessation of therapy.
Similar beneﬁcial effects were seen in a recent randomized
trial using an extended release sildenaﬁl compared with
placebo20 in scleroderma patients. No studies have been
performed to demonstrate effectiveness of sildenaﬁl in
treating primary RS; however, the microcirculatory
improvement seen in secondary RS suggest that there
may be a role for use of these agents in primary RS as well.
Tadalaﬁl and vardenaﬁl have longer half-lives than
sildenaﬁl but have been less well studied in RS. While tada-
laﬁl has been shown to be efﬁcacious in case series and
small open-label pilot studies, randomized trials using
tadalaﬁl as monotherapy have not shown signiﬁcant beneﬁt
in patients with secondary RS.21 However, as combination
therapy with other vasodilators, tadalaﬁl use resulted in
improved frequency and duration of attacks and ulcer
healing.22 In a small randomized crossover trial, improved
clinical symptoms were noted in patients treated with
vardenaﬁl compared with placebo.23
Nitrates. Nitrates have been used in the treatment of
RS as oral, topical, or intravenous preparations but, in
general, are not ﬁrst-line therapy. All forms are limited by
side effects, particularly headaches and hypotension.
Topical nitrates in the form of 2% nitroglycerine ointment
or as a transdermal patch can be applied locally to an
ischemic ﬁnger, and have been shown to be effective in the
treatment of RS in randomized controlled trials.24
Endothelin inhibitors. Endothelin is a potent endog-
enous vasoconstrictor. Bosentan is an endothelin receptor
antagonist is currently used to treat pulmonary hyperten-
sion. In the RAPIDS-2 trial, bosentan was shown to
signiﬁcantly decrease the incidence of new digital ulcers in
patients with scleroderma, although there was no change in
rates of ulcer healing, nor in pain or disability.25
Prostaglandins and analogues. Prostacyclins are
vasodilators that have been used to treat critical digital
ischemia secondary to ﬁxed occlusive disease. Epoprostenol
is a naturally occurring prostaglandin with vasodilatory
and antiplatelet actions given as a continuous intravenous
infusion. In one double-blind, placebo-controlled study,
12 patients with severe RS receiving intravenous epopros-
tenol experienced a signiﬁcant increase in ﬁngertip skin
temperature and laser Doppler ﬂow. However, improved
blood ﬂow was not sustained and beneﬁcial effects were
gone after 1 week.26Iloprost is a prostacyclin analogue reported to reduce
the severity, frequency, and duration of RS attacks and
promote healing of ischemic ulcers. In scleroderma,
complete healing of ulcers was observed 10 weeks after
treatment in six of seven subjects receiving intravenous
infusion of iloprost administered as a 6-hour infusion
over 5 consecutive days compared with no healing of ulcers
in subjects treated with saline placebo.27
Intravenous iloprost was directly compared with oral
nifedipine in two randomized controlled trials. Forty-six
subjects with systemic sclerosis were randomized to receive
intravenous iloprost over 8 hours for 5 consecutive days,
then once every 6 weeks. Raynaud’s severity score (0-10
scale measuring overall perceptions of disease severity)
was decreased and skin thickening was reduced. The study
was limited by adverse effects of headache, nausea, and
vomiting during iloprost infusion.28 In another study, 12
patients with systemic sclerosis were treated with iloprost
administered by intravenous infusion on 3 consecutive
days for 8 hours or randomized to nifedipine orally. Both
Fig. Treatment algorithm for Raynaud’s syndrome (RS).
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RS attacks, and improved ulcer healing. Hand temperature
and blood ﬂow increased with iloprost but not
nifedipine.29
Oral formulations of iloprost have failed to show any
signiﬁcant improvement for RS or digital ischemia. A
multicenter trial of 143 patients with RS secondary to
scleroderma randomized to oral iloprost or placebo found
no signiﬁcant difference in the number or duration of RS
attacks.30 Another trial of 103 patients with scleroderma
and RS showed only minimal beneﬁt with oral iloprost,
but adverse side effects often required discontinuation of
the medication.31 Lack of beneﬁt of oral iloprost limits its
overall applicability.
Surgical therapy. Surgical and other invasive therapies
for RS are listed in Table II.
The evidence regarding thoracic sympathectomy was
recently summarized by Coveliers and associates.32 Sympa-
thectomy is rarely if ever indicated for those with primary
RS, in which recurrence rates are high, but may be effective
in some patients who have critical ischemia of the digits, in
particular to alleviate pain. Currently, thoracoscopic
sympathectomy has supplanted open cervicothoracic
sympathectomy as the technique of choice.
Adventitial stripping of hand and digital arteries has
been successful in healing ulcers and improving ischemicpain.33,34 Results are anecdotal with no controlled trials
comparing digital arterial sympathectomy with other less
invasive treatment modalities. Therefore, its use in general
is discouraged, and should only be considered in refractory
cases with risk for tissue loss.
Percutaneous sympathetic blockade with a variety of
agents, including mepivacaine and bupivacaine35 has also
been shown to be an effective treatment for refractory
RS. A 2-week infusion of mepivacaine through a thoracic
sympathetic catheter placed in the T2 vertebral segment
was shown to facilitate ulcer healing in refractory secondary
RS.36 Recently, a chemical sympathectomy produced by
injecting botulinum toxin adjacent to the digital arteries
has been proposed.37 Botulinum toxin is injected into the
interstitial space around the digital neurovascular bundles.
The technique and dosage are not yet standardized. Symp-
tomatic relief has been reported in patients with refractory
RS; however, hand muscle weakness is a potential
complication.
Transcutaneous nerve stimulation has also been used in
some patients to induce vasodilation with varying results.38
Spinal cord stimulators are occasionally indicated for the
treatment of various intractable pain syndromes of the
upper extremities. There are several case reports of the
use of spinal cord stimulators for the treatment of severe
RS.39A spinal cord stimulator may reduce pain and
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trophic lesions.
Behavioral and alternative therapies. Behavioral and
alternative therapies for RS are listed in Table III.
Temperature biofeedback is a technique whereby
patients are taught methods of self-regulation of skin
temperature. Biofeedback has been studied in randomized
trials with variable results. In small randomized controlled
trials with fewer than 30 subjects, investigators demon-
strated signiﬁcant improvements in frequency and severity
of vasospastic attacks in the group of patients receiving
biofeedback.40,41 In one large (n ¼ 313) randomized,
multicenter trial, biofeedback was inferior to a control
group treated with nifedipine, with 56% fewer RS attacks
in the nifedipine group compared with the biofeedback
group.3 While the results of this study lessened overall
enthusiasm for the use of biofeedback to treat RS, a criti-
cism of this trial was the fact that only 35% of the subjects
in the biofeedback group were able to successfully learn
handwarming techniques. There is a learning curve with
biofeedback, and the results may depend on the training.
Behavioral therapy may help some, but not all can learn
temperature control techniques.
Acupuncture may be of beneﬁt in some patients. In
a small, randomized trial, acupuncture was found to be
effective in reducing the frequency and severity of attacks
in patients with primary RS. The mechanism of action is
believed to be stimulation of sensory nerves, causing release
of vasodilators such as substance P and calcitonin gene-
related peptide.42
Seredrine, a high-potency extract of Ginkgo biloba,
was evaluated in a randomized placebo-controlled trial in
patients with primary RS.43 Patients randomized to the
treatment group experienced a 56% drop in event rates
compared with 27% in the placebo group following 10
weeks of treatment. In contrast, there were no differences
in the duration and severity of attacks, nor were any differ-
ences in hemodynamic endpoints observed. This was,
however, a small pilot study with only limited statistical
power.
Laser therapy has been investigated as a potential treat-
ment for a variety of vascular and rheumatologic disorders
including RS. While most reports are anecdotal, a recent
randomized controlled trial evaluated low level laser
therapy with a 685 nm wavelength diode laser versus
sham therapy.44 Forty-eight subjects underwent treatments
for 3 weeks with ﬁve sessions per week. Frequency and
intensity of RS attacks were signiﬁcantly reduced in the
laser treated group to sham therapy.
DISCUSSION
The treatment for RS depends on the underlying path-
ophysiologic mechanism and severity of symptoms. A sug-
gested algorithm based on the author’s practice is
presented in the Fig. Vasodilator medications are more
effective in patients with primary RS. Individuals with
secondary RS often have ﬁxed obstructive arterial disease,
and vasodilators are less effective or at times have no beneﬁtat all. While a number of medications are routinely used for
vasospasm, there are no currently available drugs that are
speciﬁcally U.S. Food and Drug Administration-approved
for the treatment of RS. Choosing the one best medication
has been difﬁcult owing to a lack of large prospective,
randomized, double-blind studies comparing the efﬁcacy
of different medications. There is signiﬁcant placebo effect
in published clinical trials ranging from 20% to 40%, an
important factor when interpreting the results of uncon-
trolled trials. Most clinical trials rely on the patient’s self-
assessment of frequency and severity of RS episodes, and
objective conﬁrmation of beneﬁt has been difﬁcult to
determine. For purely vasospastic RS, the calcium channel
blockers remain the most frequently used medication,
although many vasodilating medications have been shown
to be efﬁcacious.
In most cases, digital ulcers can be managed conserva-
tively. Local débridement of dead tissue or removal of the
ﬁngernail is sometimes necessary, but partial or complete
phalangectomy may be necessary in 10% to 20% of patients.
For patients with refractory ulcerations, the phosphodies-
terase V inhibitors, as well as either central or digital sympa-
thectomy, have shown promise but can not yet be
considered standard of care.REFERENCES
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